These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9543466)

  • 21. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living.
    Gélinas I; Gauthier S; Cyrus PA
    J Geriatr Psychiatry Neurol; 2000; 13(1):9-16. PubMed ID: 10753002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats.
    Giovannini MG; Scali C; Bartolini L; Schmidt B; Pepeu G
    Eur J Pharmacol; 1998 Jul; 354(1):17-24. PubMed ID: 9726626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit.
    Gil-Bea FJ; García-Alloza M; Domínguez J; Marcos B; Ramírez MJ
    Neurosci Lett; 2005 Feb; 375(1):37-41. PubMed ID: 15664119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats.
    Scali C; Casamenti F; Bellucci A; Costagli C; Schmidt B; Pepeu G
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1067-80. PubMed ID: 12111444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimer's disease.
    Lin HQ; Ho MT; Lau LS; Wong KK; Shaw PC; Wan DC
    Chem Biol Interact; 2008 Sep; 175(1-3):352-4. PubMed ID: 18573242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metrifonate improves associative learning and retention in aging rabbits.
    Kronforst-Collins MA; Moriearty PL; Schmidt B; Disterhoft JF
    Behav Neurosci; 1997 Oct; 111(5):1031-40. PubMed ID: 9383522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of chronic metrifonate treatment on cholinergic enzymes and the blood-brain barrier.
    Rakonczay Z; Papp H
    Neurochem Int; 2001 Jul; 39(1):19-24. PubMed ID: 11311445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group.
    Blass JP; Cyrus PA; Bieber F; Gulanski B
    Alzheimer Dis Assoc Disord; 2000; 14(1):39-45. PubMed ID: 10718203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.
    Relkin NR
    Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats.
    Kumar A; Seghal N; Padi SV; Naidu PS
    Eur J Pharmacol; 2006 Dec; 551(1-3):58-66. PubMed ID: 17027965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of subchronic administration of metrifonate on cholinergic neurotransmission in rats.
    Hinz VC; Kolb J; Schmidt BH
    Neurochem Res; 1998 Jul; 23(7):931-8. PubMed ID: 9690734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice.
    Volpicelli-Daley LA; Duysen EG; Lockridge O; Levey AI
    Ann Neurol; 2003 Jun; 53(6):788-96. PubMed ID: 12783426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.
    Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
    Alzheimer Dis Assoc Disord; 1996; 10(3):124-31. PubMed ID: 8876775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Alzheimer disease. Irreversible AChE inhibition with metrifonate].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1998 Aug; 21(8):250. PubMed ID: 9758555
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study.
    Cutler NR; Jhee SS; Cyrus P; Bieber F; TanPiengco P; Sramek JJ; Gulanski B
    Life Sci; 1998; 62(16):1433-41. PubMed ID: 9585171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of subchronic metrifonate treatment on cerebral glucose metabolism in young and aged rats.
    Poindessous-Jazat F; Schmidt BH; Bassant MH
    Eur J Pharmacol; 1998 Dec; 363(1):17-28. PubMed ID: 9877077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.
    Kaufer D
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():8-14. PubMed ID: 9718229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.
    Braida D; Sala M
    CNS Drug Rev; 2001; 7(4):369-86. PubMed ID: 11830755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of cholinergic transmission enhances excitability of hippocampal pyramidal neurons and ameliorates learning impairments in aging animals.
    Disterhoft JF; Matthew Oh M
    Neurobiol Learn Mem; 2003 Nov; 80(3):223-33. PubMed ID: 14521865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.